Go to main content | Go to main menu | Go to search

Project information
Development of new MUS81 nuclease inhibitors as chemical biology probe with clinical progression

Information

This project doesn't include Faculty of Arts. It includes Faculty of Medicine. Official project website can be found on muni.cz.
Project Identification
MUNI/M/1894/2014
Project Period
3/2015 - 12/2017
Investor / Pogramme / Project type
Masaryk University
  • Grant Agency of Masaryk University
  • INTERDISCIPLINARY - Interdisciplinary research projects
MU Faculty or unit
Faculty of Medicine
Other MU Faculty/Unit
Faculty of Science
Other MU Faculty/Unit
Faculty of Informatics
Other MU Faculty/Unit
Central European Institute of Technology

The proposed research is envisioned to yield new small-molecule inhibitors of human MUS81 endonuclease. MUS81 plays critical role in resolution of late replication and recombination intermediates essential for proper segregation of chromosomes during mitosis. Its absence leads to accumulation of anaphase bridges, chromosomal breaks and fusions. Recent literature indicates that MUS81 represents a very promising target for pharmacological intervention, especially in the area of new anticancer therapies. It should be noted that until 2014, no crystal structure of human MUS81 was known. This, together with the fact that no small-molecule inhibitors of MUS81 have been reported yet, presents an excellent starting point for academic high-risk/high-gain project. This project represents unique interdisciplinary approach for proper medicinal chemistry optimization of our proprietary hit (compound 1B) together with its extensive in vitro and in vivo characterization. Furthermore, we will identify synthetic lethal partners for MUS81 deficiency with primary focus on clinically relevant genes. This together should lead to advanced leads that will be suitable for further preclinical (and possibly clinical) progression.

Publications

Total number of publications: 12

2018

2017

2016

Previous 1 2 Next

You are running an old browser version. We recommend updating your browser to its latest version.